NCT03137199 (ASTEC) is a Phase 1 clinical trial of hMSCs in Asthma, sponsored by Marilyn Glassberg.

Who is sponsoring NCT03137199?

NCT03137199 is sponsored by Marilyn Glassberg.

What drugs are being tested in NCT03137199?

Interventions in NCT03137199: hMSCs.

Is NCT03137199 still recruiting?

NCT03137199 is currently terminated. Last updated 21 May 2020.

Last reviewed 2020-05-21 · How we verify

NCT03137199: ASTEC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma

Terminated Phase 1 Last updated 21 May 2020

What this trial tests

Phase 1 trial testing hMSCs in Asthma in 3 participants. Terminated before completion.

Timeline

22 June 2017

Primary endpoint
3 March 2020

29 April 2020

Quick facts

Lead sponsor	Marilyn Glassberg
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	22 June 2017
Primary completion	3 March 2020
Estimated completion	29 April 2020
Sites	1 location across United States

Drugs / interventions tested

hMSCs — full drug profile →

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Marilyn Glassberg — full company profile →

Who can join

Adults 18 to 65, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1 investigation will be performed to test the safety of two doses of bone marrow-derived MSCs (20,000,000 and 100,000,000) administered via peripheral intravenous infusion.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives.
Harrell CR, Sadikot R, Pascual J, Fellabaum C, et al · · 2019 · cited 144× · PMID 31191672 · DOI 10.1155/2019/4236973
The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes for Orthopedic Diseases Treatment.
Malekpour K, Hazrati A, Zahar M, Markov A, et al · · 2022 · cited 73× · PMID 34169411 · DOI 10.1007/s12015-021-10185-z
Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives.
Abreu SC, Lopes-Pacheco M, Weiss DJ, Rocco PRM. · · 2021 · cited 69× · PMID 33659247 · DOI 10.3389/fcell.2021.600711
Crucial Role of Extracellular Vesicles in Bronchial Asthma.
Nagano T, Katsurada M, Dokuni R, Hazama D, et al · · 2019 · cited 35× · PMID 31137771 · DOI 10.3390/ijms20102589
Current therapeutic strategies for respiratory diseases using mesenchymal stem cells.
Wang MY, Zhou TY, Zhang ZD, Liu HY, et al · · 2021 · cited 21× · PMID 34766151 · DOI 10.1002/mco2.74
Mesenchymal Stem/Stromal Cells in Asthma Therapy: Mechanisms and Strategies for Enhancement.
Huang S, Li Y, Zeng J, Chang N, et al · · 2023 · cited 14× · PMID 37318186 · DOI 10.1177/09636897231180128
Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic.
Yuan D, Bao Y, El-Hashash A. · · 2024 · cited 10× · PMID 38765802 · DOI 10.62347/jawm2040
Emerging Cell-Based Therapies in Chronic Lung Diseases: What About Asthma?
Cereta AD, Oliveira VR, Costa IP, Afonso JPR, et al · · 2021 · cited 7× · PMID 33959015 · DOI 10.3389/fphar.2021.648506

Verify or expand the search:

Other trials of hMSCs

Trials testing the same drug.

NCT02625246 — Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis · Phase 1 · completed

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Marilyn Glassberg trials

Trials by the same sponsor.

NCT02625246 — Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03137199 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Marilyn Glassberg
Last refreshed: 21 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03137199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing